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Summary Cell lines resistant to adriamycin and amsacrine were derived from cloned sublines of the human T
cell line Jurkat. Most of the lines resemble atypical MDR cells (Danks et al., 1987; Beck et al., 1987). Thus,
resistant Jurkat sublines were cross resistant to several topoisomerase II inhibiting drugs but had low or no
resistance to other classes of drugs, resistance was not reversed by verapamil, Pgp was not overexpressed, and
drug accumulation was unaltered in resistant compared to parental (control) sublines. Other findings were that
anthracycline metabolism differed between resistant and parental sublines, and that resistant sublines displayed
altered expression of small polypeptides (<20K MW) and an 85K MW protein. Drug resistant cells showed
resistance to the production of drug induced cytogenetic aberrations, DNA breaks, and protein-DNA
complexes. Resistance was not mediated by altered binding of drugs to DNA or by increased repair of DNA
damage. Indirect evidence suggests that the resistant cells had an altered drug-DNA-topoisomerase II
association. The study highlights the complex relationships between DNA breaks, cytogenetic aberrations,
protein-DNA complexes and drug cytotoxicity, and shows that the relationships differ for adriamycin and
amsacrine, suggesting some differences in the modes of action and/or resistance for the drugs and cell lines.
Resistance of cancer cells to chemotherapeutic agents may be
an inherent property of a tumour, or may develop during the
course of treatment, perhaps due to mutagenising effects of
drugs used (Shoemaker et al., 1983; Kees, 1987). Recently
observed mechanisms of drug resistance include reduced drug
accumulation, altered drug targets, elevated DNA repair and
altered metabolism of drugs (Curt et al., 1984). The problem
of multidrug resistance (MDR) - where tumour cells become
cross-resistant to a number of drugs after exposure to a
single drug - is particularly intriguing. Drugs involved in the
cross resistance are often structurally unrelated and have
different mechanisms of action. MDR cells typically have
elevated drug efflux, increased expression of a 170K MW
permeability glycoprotein (Pgp) and double minutes (dmins)
or homogeneously staining regions (HSRs) on chromosomes.
In human MDR cells HSRs are often observed at the Pgp
gene locus on the q arm of chromosome 7 (Fairchild et al.,
1987). Amplification of genes encoding Pgp may cause over-
expression of the protein, although elevated transcription can
precede amplification (Shen et al., 1986). Analogy with
bacterial transport systems suggests that Pgp functions as a
membrane transport protein to actively pump drugs from
cells (Ames, 1986).
The term 'atypical MDR' was coined by Danks et al.
(1987) to describe cells cross resistant to several topoiso-
merases inhibiting drugs but sensitive to Vinca alkaloids.
Resistance of these human leukaemic cells was not mediated
by increased drug efflux, and neither Pgp expression nor mdr
transcripts were detected (Danks et al., 1987; Beck et al.,
1987). In other reports of resistance (Pommier et al., 1986;
Per et al., 1987) or hypersensitivity (Robson et al., 1987) to
topoisomerase II inhibiting drugs, it has been suggested that
quantitatively or qualitatively altered topoisomerase II or a
topoisomerase II modifying activity affects the altered pro-
duction of drug-induced protein-associated DNA breaks ob-
served in such cells.
In this study, clonal sublines of a human leukaemic T cell
line (Jurkat) were used to develop in vitro drug resistance to
two clinically useful chemotherapy drugs, adriamycin and
amsacrine. Properties of resistant and parental drug-sensitive
(control) sublines were compared in an attempt to elucidate
the mechanism(s) of resistance involved.
Methods
Materials
Cytotoxic drugs were obtained as pharmaceutical prepara-
tions, except for amsacrine which was a gift from the Cancer
Research Laboratory, University of Auckland School of
Medicine. Standard samples of daunorubicin, adriamycin and
their metabolic degradation products were generous gifts
from Farmitalia Carlo Erba Ltd, Italy. Antisera were pro-
duced by immunisation of New Zealand white rabbits with
washed intact Jurkat cells (anti-Jurkat), PHA-stimulated
human T cells (anti-PBLT) or JL AMSA cells (anti-AMSAR).
Non-immune serum (NRS) was obtained from the same
rabbits before immunisation.
Selectionfor drug resistance
Clonal Jurkat sublines Bi, B2 and Little (previously charac-
terised by Snow & Judd 1987, now generally referred to as
JB1, JB2 and JL) were used to select sublines which could
grow in the continuous presence of adriamycin or amsacrine.
Using stepwise increases in drug concentrations, between 6
and 10 months was required to obtain sublines resistant to
200 nM adriamycin (JL adria and JB1 adria) or 1 j4M amsac-
rine (JL AMSA, JB1 AMSA and JB2 AMSA). One subline
(JL adria 500) was selected for resistance to 500 nM adria-
mycin. In some experiments, two or three subcultures of the
same subline were assayed separately (e.g. JL control 1, JL
control 2, and JL control 3). In every case, control and
resistant sublines had been cultured for the same length of
time since selection for resistance was initiated. Resistant
sublines had growth rates and viabilities equal to those of the
corresponding control sublines.
Cytotoxicity assay
Between 20 x 104 and 40 x 104 cells per test were incubated
with a range of drug concentrations at 37°C for 3 days as
1 ml cultures in 24 well plates before cell density was deter-
mined using a haemocytometer. The IC_0 is the drug concen-
tration required to decrease cell density to 50% of that in the
untreated culture after incubation for 3 days. The resistance
factor (R factor) of a subline is defined as:
IC50 of drug-resistant subline for a particular drug
IC50 of control subline
Modulation of drug resistance was tested by comparing ICos
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and R factors of cytotoxic drugs with and without 10 4M
verapamil, 1OgM chlorpromazine or 5 fg ml' amphotericin
B.
Measurement ofdrug accumulation/retention
Cells were resuspended in RPMI medium at 37°C (2 x 106
cells/ml) and appropriate amounts of drug added. After
incubation at 37°C, cells were centrifuged (5 min, 400g, room
temperature), and extracted as described below. Centrifuga-
tion at 4°C was not used since this caused precipitation of
drugs (particularly adriamycin), which then pelleted with
cells. Cells were not washed before extraction because others
observed significant drug efflux within seconds (Kessel &
Wheeler, 1984), or minutes (Yanovich & Taub, 1983) of
resuspending cells in drug-free medium. Drawn out pasteur
pipettes enabled efficient aspiration of supernatant from
pellets. To determine drug retention, cells were resuspended
in drug-free prewarmed medium, incubated at 37°C, then
centrifuged and extracted. The effect of 10 mM sodium azide
on drug uptake and retention was tested in PBS containing
5% FCS.
Adriamycin was extracted from cells by 3 ml of an aque-
ous solution of 0.3 M HCI and 50% ethanol (Streeter et al.,
1986). After extraction for I h at 37°C, samples were cen-
trifuged (5 min, 400g, room temperature) and fluorescence
was measured in a Shimadzu model RF-540 spectrofluoro-
photometer (excitation 495 nm, emission 552 nm). Fluores-
cence in samples was stable for at least I week. Adriamycin
was quantitated from a linear standard curve prepared from
the fluorescence of known concentrations of adriamycin.
Amsacrine was extracted from drug treated cells by 0.3 M
NaOH, 50% ethanol for 3 days at room temperature. Under
these conditions, amsacrine hydrolysed to highly fluorescent
9-aminoacridine, reaching approximately 50% conversion
after 3 days. Hydrolysis was linear with respect to the initial
amsacrine concentrations up to 5 LM. Fluorescence of cen-
trifuged samples was measured using excitation 410 nm,
emission 485 nm. Amsacrine was quantitated from standard
curves prepared using known amsacrine concentrations incu-
bated in alkaline ethanolic solution over the same time
period.
Radioisotope labelling
Exponentially growing cells were labelled with 25 laCi ml-'
35S-methionine for between 6 and 14 h in methionine-free
culture medium containing dialysed FCS.
LPO-catalysed radioiodination of cell surface proteins was
performed as previously described by Snow and Judd (1987).
Detergent extraction ofproteins
Detergent extraction mixtures contained 0.5-2 x I07 cells ml.
35S-met labelled cells were sequentially extracted by NP40,
DOC/Brij 58 then SDS to solubilise progressively more hy-
drophobic proteins. Washed cells were resuspended in 1%
NP40, 50 mM Tris HCI (pH 6.8), 1 mM PMSF, incubated on
ice for 45 min then centrifuged (10 min, 400g, 4°C) to obtain
NP40 extract. Pelleted cells were resuspended in 0.5%
sodium deoxycholate (DOC), 1% Brij 58, 10 mM NaCI,
3 mM MgC12, 10 mM Tris HCI (pH 7.4), 1 mM PMSF, incu-
bated on ice for 45 min then centrifuged to obtain DOC/Brij
extract. Cell pellets were finally resuspended in SDS-PAGE
sample buffer without 2-mercaptoethanol at room tempera-
ture. Several 5 s sonications were immediately performed (on
ice) to shear DNA.
Protein analysis
Proteins were separated by SDS-PAGE using 5 to 15%
acrylamide gradients. Fluorography of gels was used to
visualise radiolabelled proteins.
Analysis ofanthracycline metabolism
Drug incubations and separation ofmetabolites by TLC were
performed as previously described by others (Ahmed et al., 1978; Ahmed, 1985). Reaction mixtures contained cell homo-
genate, 3H-daunorubicin (DNR, 5 Cimmol-', NEN), ± 0.5
mM NADPH in 0.25 M Tris, pH 8.5 (final volume 50yl). After incubation at 37°C, 20yl isopropanol was added, and
the mixture was saturated with ammonium sulphate. Aqueous and isopropanol phases were separated by a IOs centrifugation in a microfuge. Aliquots of the isopropanol phase were separated on silica gel TLC plates using CHC13:CH3OH:H20 (80:20:3, v/v). TLC plates containing radiolabelled drug were briefly placed in 20% (w/v) PPO in
acetic acid then allowed to dry before exposing to X-ray film.
Cell homogenates were prepared from sonicated cells resus-
pended (108 cells/ml) in half-strength PBS without magnes- ium or calcium. Samples were held on ice, and sonicated with
several 5 s pulses. Protein concentrations were determined by the Bradford assay (Bradford, 1976).
Cytogenetic analyses
Chromosomes were G-banded as previously described (Snow & Judd, 1987) and karyotypes determined according to the
International System for Cytogenetic Nomenclature (1978).
Assayfor cytogenetic damage
Logarithmically growing cell cultures were treated for 1 h
with adriamycin or amsacrine at 37°C, then cells were pellet- ed and resuspended in fresh RPMI medium containing 0.06 fig ml-' colchicine. After incubation for 3 h at 37°C, cells were harvested and metaphase spreads were prepared and stained. Drug dosages were chosen from preliminary experiments to yield easily discernable damage.
Fluorescence assay
Cells resuspended (to 106 cells/ml) in prewarmed PBS con-
taining 5% FCS were incubated with adriamycin, amsacrine,
or H202 for 1 h at 37°C. Aliquots of cells (500ftl) were
centrifuged (5min, 400g, room temperature) then resus-
pended in 500ftl of PBS at room temperature. Aliquots were
taken through procedures, A, B or C as previously described
(Kanter & Schwartz, 1982).
A: 1 ml of 0.1M NaCI was added, followed by 500 IlI buffer and sonication for 15 s.
B: 500ftl of 0.1 M NaOH was added, followed by incuba-
tion in a still, dark position for 30min before addition of 500 il of 0.1 M HCI and 500tlA buffer, then sonication for
15S.
C: 500 gAl of 0.1 M NaOH was added, followed by a S s
sonication. After standing for 30min, 500 gAl of 0.1 M HCI and 500iLl buffer were added and samples were sonicated for
lSs.
Sonications were done at a power level which produced foaming of samples. Buffer contained 0.16% (w/v) sodium lauroyl sarcosinate, 0.04 M disodium EDTA, 1 lAgml-' Hoechst-33258 dye, in 0.2 M potassium phosphate, pH 7.4. Hoechst-33258 was added to buffer on the day of experi- ments. Samples were left for several hours at room temper- ature before reading fluorescence levels at excitation 353 nm, emission 451 nm.
For each drug treatment the relative fluorescence (F) was calculated from:
F B-C
A-C
where B-C is a relative measure of duplex DNA, and A-C
represents total DNA.
For the assay of DNA repair, Little cells were treated for
1 h with amsacrine or adriamycin, then centrifuged and
resuspended in prewarmed PBS containing 5% FCS. Resus-DRUG RESISTANT CELL LINES 19
pended cells were incubated at 37°C for varying periods
before assays for DNA breaks were performed. Prolonged
incubation of cells in PBS/5% FCS reduced cell viability (to
between 70 and 80% viable cells after 3 h at 37°C). There-
fore, fluorescence values were determined in treated and non-
drug-treated samples (each in duplicate) for all post-incu-
bation/repair times. Damage remaining during incubation in
drug-free medium was calculated from:
the F value obtained using drug-treated samples
the F value obtained using untreated samples
Thus, total repair ofdrug-induced damage would give a ratio
of 1.
Assayforprotein-associated DNA breaks
Cellular DNA was radioactively labelled by incubating logar-
ithmically growing cells with 2ftCi/ml [methyl-3H]-thymidine
(91 Ci mmol'I, Amersham) for approximately 16 h.
In the assay for protein-DNA complex (PDC) formation
(Rowe et al., 1986), cells were washed twice in cold RPMI
1640 then resuspended in RPMI 1640 containing 5% FCS
(prewarmed to 37°C) at a density of 105 cells ml. One ml
aliquots of cell suspension were placed in wells of 24 well
plates which contained adriamycin or amsacrine solutions.
After incubation at 37°C, plates were centrifuged and med-
ium aspirated from the wells. Prewarmed (65°C) lysis solution
(800 dl) was added to each well and samples were left at
room temperature for 5- O min before being transferred to
Eppendorf tubes. As soon as 200 il of 325 mM KCI (pre-
warmed to 37°C) was added, tubes were vortexed vigorously
for 10s. Samples were cooled on ice for 10min then cen-
trifuged in a microfuge at 4°C for 10 min. Pellets were
resuspended in 1 ml ofwash solution, deposited on Whatman
GF/C filters and filtered by gravity. Filters were then washed
three times with wash solution and dried before determining
radioactivity in a scintillation counter. Fold stimulation of
PDC formation was calculated from:
dpm bound to filters from drug-treated samples
dpm bound to filters from non-drug-treated samples
Lysis solution contained 1.25% SDS, 0.4mgml salmon
sperm DNA, 5 mM EDTA, pH 8.0. Wash solution contained
100mM KCI, 1 mM EDTA, 10mM Tris-HCl, pH 8.0.
Drug-DNA binding assay
Binding of adriamycin or amsacrine to DNA was assessed by
quenching of Hoechst-33342 fluorescence as previously des-
cribed (Andersson et al., 1986). At the wavelengths used to
measure Hoechst fluorescence (excitation 355 nm, emission
450nm), no fluorescence was detected from adriamycin or
amsacrine at the drug concentrations used in binding experi-
ments.
Cells at a density of 106 cells ml were incubated for 1 h at
37°C in PBS containing 5% FCS and 0.5Lg ml1' Hoechst-
33342. After centrifugation and resuspension in fresh pre-
warmed PBS/FCS, various concentrations of adriamycin or
amsacrine were added to aliquots of cell suspension. Hoechst
fluorescence was determined after incubation at 37°C.
Results
Cross resistance profiles
Table I lists IC50 values and R factors from cytotoxicity
assays using a range of drugs with JL, JB1 and JB2 sublines.
Generally, resistant sublines exhibited high resistance
(R> 20 x) to amsacrine, mitoxantrone and VM-26, moder-
ate resistance (R5-15 x) to adriamycin, and low or no
resistance (R <5 x) to mitomycin C, araC, methotrexate,
vincristine and camptothecin. Exceptions to this pattern in-
cluded moderate resistance of JL AMSA to VM-26, JB1
adria to mitoxantrone, and JB1 adria to vincristine.
Stability of resistance in the JL AMSA subline (resistance
to 1 ytM AMSA) was tested by growing the subline in drug-
free medium for 6 months. Cytotoxicity assays showed that
JL AMSA maintained high resistance to amsacrine and
moderate resistance to adriamycin (data not shown).
In previous reports, amphotericin (Krishan et al., 1985),
calcium antagonists such as verapamil (Merry et al., 1986)
and calmodulin inhibitors such as chlorpromazine (Tsuruo,
1983) have been used to obtain partial reversal of drug
resistance. In this study, R factors for amsacrine or adria-
mycin were unaffected by 10iLM verapamil, 10 !M chlor-
promazine or 5l ml1' amphotericin B (data not shown).
Drug accumulation and retention
Because of different average cell sizes for each of the sub-
lines, drug accumulation data has been calculated using cell
volumes (assuming spheroid shape) as well as cell numbers.
Average cell diameters were 13, 14, 10 and 12 l.M for JL
control subculture 1, JL control subculture 2, JL AMSA and
JL adria cells, respectively, giving theoretical cell volumes of
11.6, 14.5, 5.3 and 9.1 x 10-l1, respectively.
Figure la,b shows drug content of cells incubated with
2 ILLM amsacrine for various times, then post-incubated in
drug-free medium. For each subline, maximum accumulation
occurred after 45 min of incubation, followed by decreases in
drug content between the 45- and 90 min time points. Maxi-
mum accumulation values were 2.9, 4.1, 2.1, 3.1 moles/cell
(x 10-16) or 248, 283, 388, 336 .tM for JL control 1, control
2, AMSA and adria sublines respectively. JL control I had
the lowest drug retention which was 59% of drug accumu-
lated after 45 min for a 2 h post-incubation without drug.
Although similar profiles were obtained by incubating cells
with I M or SYlM amsacrine, a IOYM incubation yielded
different results - no plateau or peak accumulation was
reached during a 90 min incubation (Figure lc,d). After
45 min of incubation with amsacrine, intracellular drug levels
Table I ICo and resistance factors of Jurkat sublines
IC50 (nM)/Rfactor
Drug JLcon JL AMSA JL adria JBI con JBI AMSA JBI adria JB2 con JB2 AMSA
Amsacrine 78.3/- 3570/46 2160/28 28.8/- 2600/90 212/7.3 62.5/- 2400/38
Adriamycin 30.5/- 146/5.0 329/10.9 27.7/- 200/7.2 293/10.6 31/- 265/8.5
Mitoxantrone 6.3/- 133/21 214/34 1.6/- 50/33 13.5/8.5 5.3/- 227/57
Mitomycin C 110/- 142/1.3 154/1.4 130/- 175/1.3 150/1.2 130/- 175/1.3
Vincristine 3.5/- 2.1/0.6 6.0/1.7 0.89/- 1.3/1.5 8.5/9.6 0.84/- 0.76/0.9
AraC 22.3/- 23.5/1.1 42.5/1.9 51/- 69/1.5 57/1.1 36/- 35/1.0
Methotrexate 5.6/- 8.2/1.5 7.5/1.3 3.1/- 9.5/3.1 7.8/2.5 8.0/- 7.8/1.0
VM26 38.1/- 363/9.5 997/26 7.6/- 150/20 680/89 18.6/- 480/26
Camptothecin 0.56/- 0.63/1.1 0.62/1.1 0.39/- 0.32/0.8 0.48/1.2 0.67/- 0.64/1.0
Daunorubicin 13.5/- 46.5/3.4 79/5.9 ND ND ND ND ND
Cells were incubated with drugs for 3 days and viable cells counted. IC5o is defined as the drug concentration required to inhibit cell
growth by 50% compared to parallel untreated cultures. R factors were calculated from:
IC5o of drug resistant subline
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extracted proteins from Little sublines. Although several
differences were apparent between sublines, none consistently
correlated with drug resistance (data not shown).
NP40 extractable iodinated surface proteins revealed num-
erous differences between sublines (arrows in Figure 2). The
only consistent resistance-associated difference was increased
intensity of a protein at 85K MW, particularly from the three
amsacrine resistant sublines and to a lesser extent from JL
adria 200 and JB1 adria.
Neither immunoblotting (kindly performed by Dr D.R.
Bell) using monoclonal antibody C219 (Kartner et al., 1985)
nor silver staining detected any Pgp protein from enriched
membrane fractions of JL control, JL AMSA or JL adria
cells.
Drug metabolism
Since the glutathione detoxification system is involved in
metabolism of adriamycin (Arrick & Nathan, 1984) and
amsacrine (Shoemaker et al., 1984), possible contribution of
the system to detoxification of these drugs in resistant and
control Jurkat sublines was tested. Assays of GSH content
(Akerboom & Sies, 1981), and activities of GSH transferase
(Warholm et al., 1985), GSH peroxidase (Flohe & Gunzler,
Figure 1 Representative results for accumulation and retention
of drug in JL cells incubated with amsacrine. a, JL control 1
incubated with 2 JM amsacrine; b, JL AMSA incubated with
2 JAM amsacrine; c, JL control 2 incubated with 10 JiM amsacrine;
d, JL AMSA incubated with 10IJM amsacrine. Cells were incu-
bated with drug for up to 1.5 h. After various intervals, samples
of cells were used in assays of drug accumulation (solid lines) or
were reincubated in drug free medium for a further period to
assess drug retention (broken lines). Units on the ordinate are
moles amsacrine/cell x 10-16. Standard errors were 0.03%-3.1%
of mean fluorescence.
were 25.1, 23.2, 8.0 and 14.4 moles/cell (x 1016), or 2.1, 1.7,
1.6 and 1.5 mM, for JL control 1, control 2, AMSA and
adria sublines, respectively. The lowest retention value of
49% of accumulated drug was obtained for JL adria cells
incubated for 15 min with drug, followed by 2 h without
drug.
In similar experiments using 5, 10 or 201AM adriamycin,
each JL subline showed a relatively rapid rate of accumula-
tion before 15 min, followed by a slower, but steady rate of
accumulation up to 2 h of incubation (i.e., similar to Figure
lc,d). After a 1 h incubation in 5 JAM adriamycin, JL control
1, control 2, AMSA and adria cells accumulated 4.5, 3.2, 4.2
and 4.1 moles/cell (x 10-16), respectively. Levels of adria-
mycin retention (after 30 min in drug-free medium) in drug
resistant cells were not significantly different from those in
control cells (data not shown). The presence of 10 mM
sodium azide during either drug uptake or efflux incubation
periods did not affect adriamycin accumulation or retention
for JL control, AMSA or adria sublines, suggesting passive
drug uptake and efflux (data not shown).
Fluorescence microscopy of JL cells incubated with 20 jLM
adriamycin or 5 JiM daunorubicin for 1 h at 37°C revealed a
predominant nuclear location of each drug in JL control,
AMSA and adria cells (data not shown). Hence no
significant differences in drug accumulation or retention were
found between drug resistant and control cells.
Protein analyses
SDS-PAGE separation of proteills sequentially extracted by
NP40, DOC/Brij and SDS from 35S-met labelled JL drug-
resistant and control subline showed few differences. A broad
band at
-20 kDa was more diffuse in appearance in drug
resistant cells, while a slightly smaller, sharp band was absent
from the drug resistant cells (data not shown). Both proteins
were only extracted by SDS.
Polyclonal anti-Jurkat, anti-PBLT and anti-AMSAR anti-
sera were each used to radioimmunoprecipitate NP40-
1 2 3 4 5 6 7 8 9 10 K MW
- 221
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Figure 2 Radioiodinated proteins from drug resistant and con-
trol Jurkat sublines. Cell surface proteins were radioiodinated
using the lactoperoxidase procedure. NP40 extracts of '25I-label-
led cells were separated by SDS-PAGE and visualised by fluoro-
graphy. Lanes were loaded with equal radioactivity. Lane 1: JL
control subculture 1. Lane 2: JL control subculture 2. Lane 3: JL
AMSA. Lane 4: JL adria 200. Lane 5: JL adria 500. Lane 6: JB1
Bl control. Lane 7: JBI Bl AMSA. Lane 8: JBI adria. Lane 9:
JB2 control. Lane 10: JB2 AMSA.
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Figure 3 Time dependent production of DNR metabolites/de-
gradation products in reaction mixtures containing 3H-DNR and
cell homogenate. Homogenates of JL cells (4.0 mg ml-' protein)
were incubated with 2 1AM 3H-DNA in the presence or absence of
0.5 mM NADPH at pH 8.5 for 4.5 h or 24 h. DNR, metabolites
and possible degradation products were extracted and separated
by TLC. Spots were visualised by fluorography. Samples 1-8
were incubated for 4.5 h - NADPH: 1, 2 buffer only; 3, 4 Little
control cell homogenate; 5, 6 JL AMSA cell homogenate; 7, 8 JL
adria cells homogenate. Samples 9 to 16 were incubated for
4.5 h, + NADPH: 9, 10 buffer only; 11, 12 JL control cell homo-
genate; 13, 14 JL AMSA cell homogenate; 15, 16 JL adria cell
homogenate. Samples 18 to 25 were incubated for 24 h,
NADPH: 18, 19 buffer only; 20, 21 JL control cell homogenate;
22, 23 JL AMSA cell homogenate; 24, 25 JL adria cell homo-
genate. Samples 26 to 33 were incubated for 24 h, + NADPH: 26,
27 buffer only; 28, 29 JL control cell homogenate; 30, 31 JL
AMSA cell homogenate; 32,33 JL adria cell homogenate. Sam-
ples 17 and 34 contained DNR diluted into pH 8.5 buffer
immediately before spotting onto the TLC plate.
1984), GSH reductase (Carlberg & Mannervik, 1985) and
y-glutamylcystein synthetase (Seelig & Meister, 1985) did not
reveal any significant differences between JL control, and
drug resistant sublines (data not shown). In addition, act-
ivities of other putative drug metabolising enzymes, catalase
(Aebi, 1984), superoxide dismutase (Beauchamp & Fridovich,
1971), NADPH cytochrome P450 reductase (Strobel & Dig-
nam, 1978), aryl sulphotransferase (Sekura et al., 1981) and
xanthine oxidase (Dodion et al., 1987) were not altered in
resistant compared with control JL sublines (data not
shown).
An assay previously used to measure anthracycline reduc-
tase activity in human leukaemic and myelocytic cells
(Ahmed, 1985) was used to compare metabolism of 3H-DNR
by JL control and resistant sublines. Cell homogenates from
JL sublines (4 mg ml-') were incubated at pH 8.5 with 21LM
3H-DNR in the presence or absence of 0.5 mM NADPH for
4.5 h or 24 h at 37C. Figure 3 shows representative fluoro-
graphs obtained after sample processing and TLC. The posi-
tion of DNR (species I) was identified from direct application
of 3H-DNR (samples 17 and 34). After incubation for 4.5 h,
a small amount of a more slowly migrating species (species
II) was present in all JL cell homogenates with added
NADPH (samples 11 to 16, Figure 3). Species II was absent
from all incubated mixtures containing NADPH, but no cell
homogenate (samples 9, 19, 26, 27), and was also absent
from all mixtures incubated without NADPH (samples I to 8
and 18 to 25). After a 24 h incubation, relatively more species
II could be extracted from control cell homogenates (samples
28 and 29, Figure 3) than resistant cell homogenates (samples
30 to 33). For each subline, the relative amounts of species I
and II extracted decreased with increasing protein concentra-
tion (data not shown), however, JL AMSA consistently con-
tained 0.5 x and JL adria 0.3 x as much of species II as did
control cells. Species II was not detected from reaction mix-
tures incubated in buffers between pH 5.5 and pH 8.0 for
24 h at 37°C. Chromatography of DNR and its metabolites
suggested that species I was daunorubicin and species II
daunorubicinol.
In similar studies of amsacrine metabolism, both resistant
and control cell homogenates gave rise to identical patterns
of metabolites/degradation products (pH 6.0 and 8.5,
± 0.5 mM NADPH, for up to 24 h at 37°C).
Cytogenic analyses
JL and JB2 control and drug resistant sublines were karyo-
typed by G-banding, seeking evidence for gene amplification
(dmins, HSRs, or ABRs) which others have reported may
accompany drug resistance. Results shown in Table Ila
indicate much karyotypic instability during selection, but
little in drug resistant cells (Table IIb). This suggests that
resistant cells were also resistant to DNA damage from
cytotoxic drugs. No karyotypic features were found to cor-
relate consistently with drug resistance.
Cytogenetic damageproduced by amsacrine or adriamycin
Table III lists the number of metaphases containing various
degrees of cytogenetic damage after 1 h incubations of cul-
tures with amsacrine or adriamycin followed by 3 h incuba-
tion in fresh medium containing colchicine. For each subline,
metaphases prepared from non-drug-treated cultures con-
tained no apparent cytogenetic damage. Drug concentrations
which left approximately 50% of metaphases without dam-
age in JL control, AMSA and adria sublines were <1 1 M,
20 1LM and 50gM amsacrine, respectively and < 1.5 1AM, 5 tAM
and 25 1AM adriamycin, respectively. Pulverisation of some
chromosomes occurred after treatment of control cells with
amsacrine or adriamycin, and after treatment of JL AMSA
cells with amsacrine but not adriamycin. Generally, drug
treatment did not cause pulverisation of JL adria meta-
Table II Numbers of chromosomes and dmins in resistant, partially resistant, and control Jurkat sublines
Weeks
at this No. of Chromosomes Chromosomes Chromosomes Metaphases Range
Subline [Drug]nM [drug] spreads Icell-range Icell-mean /cell-SD with dmins dmins/cell
a JB2 con - - 34 67-250 90 29 2 1,2
AMSA 200 4 25 50-108 81 10 14 1 -4
adria 50 4 16 67-135 86 15 8 1,2,13
JL con - - 21 46-95 50 11 0
AMSA 200 8 24 45-93 53 14 2 1,2
adria 50 4 19 45-112 60 20 8 1-7
JL conI - - 20 44-131 55 22 0 -
con2 - - 23 48-132 86 18 1 1
AMSA 1000 6 29 42-205 67 48 3 1-5
adria 200 3 19 40-187 82 52 5 2-5
b JL conl - - 11 44-91 51 24 2 1
con2 - - 10 45-93 77 22 0 -
AMSA 1000 42 11 42-46 45 1.1 2 1
adria 200 42 10 43-46 45 1.1 0 -
Section a ofthe table includes data from partially resistant sublines and section bdata from resistant sublines. Ineachcasemetaphase
spreads of control sublines were analysed at the same time as the corresponding resistant/partially resistant sublines.22 K. SNOW & W. JUDD
Table III Resistance to DNA damage - cytogenetic assay
% With
% With I % With 2 % With 3/+ % With chromatid % With
Metaphases % With no chromatid chromatid chromatid chromatid exchange + dmins %
Subline [Drug] scored damage break breaks breaks exchange breaks only Pulverised
JLcontroll M AMSA 139 36 7 7 16 7 12 7 8
2AMAMSA 20 10 15 25 15 0 15 5 15
1.5gM adria 90 39 13 4 30 0 2 2 10
2AM adria 51 35 8 8 33 0 2 2 12
JL AMSA20iLMAMSA 164 47 12 05 18 1 2 4 11
3011MAMSA 91 35 16 13 15 1 2 13 5
511M adria 80 53 5 24 17 0 0 1 0
1OsM adria 70 36 17 13 34 0 0 0 0
15JAM adria 40 20 15 20 45 0 0 0 0
JL adria 401LMAMSA 41 71 12 0 7 0 5 2.5 2.5
SOjAMAMSA 40 45 25 15 10 2.5 2.5 0 0
10gMadria 50 64 18 14 8 2 0 4 0
20gMadria 140 56 18 10 8 1 1 6 0
25gM adria 40 50 22.5 17.5 10 0 0 0 0
JLcontrol, JL AMSA andJL adria cultures were treated for I h at 37°C with various concentrations ofamsacrine oradriamycin then
resuspended in fresh medium containingcolchicine. After a further 3 h incubation at 37°C, metaphasespreads wereprepared and scored
for cytogenetic damage. Data were derived from numerous experiments.
Table IV Effect of araC on resistance to DNA damage - cytogenetic assay
% With
% With 1 % With 2 % With 3/+ % With chromatid % With
Treatment Metaphases % With no chromatid chromatid chromatid chromatid exchange + dmins %
Subline before araC scored damage break breaks breaks exchange breaks only Pulverised
JL control- 30 93 0 0 0 0 7 0 0
I MAMSA 44 9 7 5 34 0 9 4 32
2 AM adria 20 0 0 0 35 0 0 0 65
JL AMSA- 62 81 11 1.5 1.5 0 0 5 0
20 LMAMSA 73 23 22 8 27 2 2 5 11
JL adria - 35 77 11 9 3 0 0 0 0
10 tMadria 20 40 0 15 40 0 0 5 0
20gMadria 30 43 20 10 20 0 0 7 0
JLcontrol, JL ASMA and JL adria cultures were treated for I h at 37°C with variousconcentrations ofamsacrine oradriamycin then
resuspended in fresh medium containing colchicine and 50gM ara C. After a further 3 h incubation at 37°C, metaphase spreads were
prepared and scored for cytogenetic damage.
Table V Effect of novobiocin on resistance to DNA damage -cytogenetic assay
% With
Treatment % With I % With 2 % With 3/+ % With chromatid % With
following Metaphases % With no chromatid chromatid chromatid chromatid exchange + dmins %
Subline novobiocin scored damage break breaks breaks exchange breaks only Pulverised
JLcontrol- 101 79 11 3 1 0 0 6 0
IllMAMSA 60 53 17 7 8 3 5 5 2
1.51Madria 25 40 20 12 20 0 0 8 0
JLAMSA- 40 90 7.5 2.5 0 0 0 0 0
201MAMSA 40 50 22.5 0 15 0 2.5 2.5 7.5
JLadria 30MAMSA 30 40 23 0 13 4 0 0 0
40 80 17.5 0 2.5 0 0 0 0 20J1Madria 31 52 26 3 13 0 0 6 0
25JMadria 42 67 14 7 10 0 2 0 0
JL control, JL AMSA and JL adria sublines were treated for 30 minwith 1mM novobiocin at 37°C, centrifuged, resuspended in
medium containing no drug, amsacrine or adriamycin for 1h, then resuspended in medium containing colchicine. After a further 3 h,
metaphase spreads were prepared and scored for cytogenetic damage.
phases, even at very high drug concentrations which reduced
the number of metaphases to less than 10% of the number
from parallel untreated cultures.
AraC has previously been shown to inhibit DNA repair of
chromosome aberrations (Preston, 1982), and it was used
here as one means of ascertaining if DNA repair was in-
creased in drug resistant cells. Comparing Tables III and IV,
and considering cytogenetic damage caused by araC alone, it
is clear that araC augmented damage produced by adria-
mycin or amsacrine treatment of JL control cells. Although
post-treatment with araC also decreased the fraction of
undamaged JL AMSA metaphases seen after amsacrine treat-
ment, the effect was smaller than for control cells. AraC
post-treatment did not significantly affect the amount of
damage caused by incubation of JL adria cells with adria-
mycin (when damage induced by ara C alone was consid-
ered).
Novobiocin inhibits binding of ATP to topoisomerase II,
thus inhibiting strand-passage activity and topoisomerase
turnover which require ATP binding and hydrolysis (Vos-
berg, 1985). It also inhibits several other ATP dependent
enzymes. Previous experiments showed the growth of JL
control, JL AMSA and JL adria sublines were similarly
retarded by novobiocin. Each subline showed an IC50 of
approximately 200 LM novobiocin in 3-day continuous ex-
posure experiments (data not shown).
Table V shows the cytogenetic damage produced when
cultures were treated with 1 mM novobiocin just prior toDRUG RESISTANT CELL LINES 23
drug exposure. Pretreatment of JL control cells with novo-
biocin reduced the level of cytogenetic damage induced by
amsacrine or adriamycin but had no effect in preventing
damage to drug resistant cells. (Statistical analysis of results
in Tables III-V indicates that these conclusions are statis-
tically highly significant).
Quantification ofDNA breaks using afluorescence assay
In this assay, F values represent the fraction of duplex DNA
versus total DNA remaining after treatment of cells with
alkali to cause unwinding of DNA at break sites. Figure 4
shows the F values obtained after treatment of JL control,
AMSA, and adria with various concentrations of amsacrine
for 1 h. F values for untreated cells were probably less than
one because of inherent nicks in cellular DNA and a small
percentage of dead cells in the culture used. Amsacrine con-
centrations required to reduce F values to 80% of the non-
drug-treated values were 0.12 JAM, 11 AM and 7.5 JAM for JL
control, JL AMSA and JL adria sublines, respectively.
Figure 4 also shows F values obtained after treatment of
JL control (Figure 4a,) JL AMSA (Figure 4b) and JL adria
(Figure 4c) sublines with various concentrations of adria-
mycin for 1 h. From these curves, the adriamycin concentra-
tions required to reduce F values to 80% of the non-drug-
treated values were 4.5 JM, 19 JM and 16JAM for JL control,
JL AMSA and JL adria sublines, respectively.
Damage to JL AMSA or JL adria DNA caused by 10 JAM
and 7 JAM amsacrine, respectively, was not significantly re-
paired after 2 h in drug-free medium (Figure Sa). In contrast,
damage to JL control DNA (in cells incubated with 0.2 JAM
amsacrine) was totally repaired within 1.5 h of incubation in
drug-free medium. In all sublines treated with adriamycin,
production of DNA breaks continued for up to 30 min after
removal of extracellular drug (Figure Sb). After this time,
each of the sublines showed only slight DNA repair.
Drug-induced PDCformation
Figure 6 shows stimulation of PDC formation in JL cells
treated with amsacrine for 1 h at 37°C. In this experiment,
2.5 fold stimulation of PDC formation required 0.7JAM,
43 JAM and 5 JAM amsacrine using JL control, JL AMSA and
JL adria sublines, respectively.
Adriamycin had an unexpected effect on PDC formation.
For each subline, stimulation of PDC formation was less
after the 2 h incubation (Figure 7b) than the 1 h incubation
(Figure 7a). Furthermore, for the drug resistant sublines,
fold-stimulation was less than 1, suggesting that adriamycin
treatment caused more DNA to pass through the filters.
Maximum stimulation of PDC formation in control cells
after a 1 h adriamycin treatment was approximately 2.3-fold
(Figure 7a), compared with approximately 18-fold stimula-
tion caused by a 1 h amsacrine treatment (Figure 6).
Drug-DNA binding within resistant and control cells
Although drug accumulation and retention were unaltered in
resistant compared with control cells, it seemed possible that
reduced association of the intercalating drugs with DNA
could affect resistance of JL AMSA and JL adria cells to
DNA damaging effects.
Hoechst-33342 fluorescence of cell suspensions or calf
thymus DNA solutions is stable for several hours at 37°C.
Uptake and retention of amsacrine or adriamycin were
unaffected by preincubation of cells with Hoechst 33342
(data not shown).
Figure 8 shows Hoechst fluorescence remaining after post-
incubation with various concentrations of amsacrine for 1 h.
Amsacrine concentrations required to reduce Hoechst fluor-
escence to 50% of the non-amsacrine-treated values were 28,
25, 23, 24 and 19JAM for JL control 1, control 2, AMSA,
adria sublines and DNA, respectively, indicating similar ams-
acrine-DNA binding in each case. Quenching of Hoechst
fluorescence in a DNA solution was only slightly more
efficient than quenching within cells. Maximum quenching of
Hoechst fluorescence occurred within 10 min of adding amsa-
crine to cells or DNA. Approximately 85% of the initial
fluorescence was restored within 5 min of transferring cells to
amsacrine-free medium, and fluorescence changed little dur-
ing the next hour. Although Hoechst fluorescence recovery
was high, 75% of the amsacrine accumulated during the 1 h
drug incubation remained in the cells. This retained amsa-
crine may represent drug sequestered into an extranuclear
compartment as previously described by Zwelling et al.
(1982).
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Figure 4 Fluorescence assay for DNA damage in the cells
treated with amsacrine -El or adriamycin *-. a, JL con-
trol cells; b, JL AMSA cells; c, JL adria cells. Cells were
incubated with various concentrations of drug in PBS/5% FCS at
37°C for I h. DNA breakage was then determined using a fluo-
rescence assay. Each point is the mean of four experiments, and
standard deviations did not exceed ± 9%. Decreasing fluores-
cence (F) values represent increasing DNA breakage. Note that
the relationship between DNA breakage and fluorescence is only
linear when data is plotted on a log/log basis.24 K. SNOW & W. JUDD
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Figure 6 Stimulation of PDC formation in JL cells treated with
amsacrine. 3H-thymidine labelled JL control 1l3, AMSA
* and adria U cells were incubated with various con-
centrations of amsacrine in RPMI medium for 1 h at 37'C, then
used in an assay for PDC formation. Fold-stimulation of PDCs
was calculated from the ratio:
3H bound to filters using drug treated cells
3H bound to filters using untreated cells
Standard deviations were calculated from triplicate samples.
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Figure 5 Repair of DNA damage in JL cells previously treated
with amsacrine or adriamycin. JL control (A), JL AMSA (-)
and JL adria (0) cells were treated for I h with 0.2 JAM, 1O JM
and 7 JAM amsacrine, respectively a, or 6 JAM, 18 JAM and 18 JM
adriamycin, respectively b. After various post-incubation periods
in drug-free PBS/5% FCS, the fluorescence assay was used to
assess DNA breakage. The repair ratio was calculated from:
F value of cells + drug
F value of cells-drug
using cells incubated for identical lengths of time in PBS/5%
FCS. For each drug treatment, the mean repair ratio was cal-
culated from two independent experiments, each containing dup-
licate incubations with each concentration of drug.
Hoechst fluorescence was reduced to 50% of the non-
adriamycin-treated values by a 1 h exposure to 1.9, 7.2, 3.2,
4.3 and 1.4 JAM adriamycin for JL control 1, control 2,
AMSA and adria cells and DNA, respectively (data not
shown). Since resistant values fell between control values, it
appears that drug binding did not differ significantly between
drug resistant and control cells. In contrast to quenching by
amsacrine, adriamycin-induced quenching was irreversible
(after reincubation of cells in drug-free medium for 30 min).
Comparisons between DNA damaging and cytotoxic effects of
drugs
It was noted that resistance to cytogenetic damage by drugs
did not reflect the resistance of JL adria and JL AMSA
sublines to drug cytotoxicity during 3 day continuous ex-
posures. Thus, the JL AMSA subline appeared less resistant
to adriamycin- or amsacrine-induced cytogenetic damage
than the Little adria subline, whereas the JL AMSA subline
was more resistant to amsacrine than the JL adria subline in
the cytotoxicity assay. Because of this discrepancy, growth
inhibitory effects of amsacrine and adriamycin were also
measured after 1 h incubations of cultures with drug at 37°C,
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Figure 7 Stimulation of PDC formation in JL cells treated with
adriamycin. 3H-thymidine labelled JL control (A), JL AMSA
(U) and JL adria (0) cells were incubated with various concent-
rations of adriamycin in RPMI medium for I h a, or 2 h b, at
37°C. Using the assay for PDC formation, fold-stimulation of
PDCs was calculated from:
3H bound to filters using drug treated cells
3H bound to filters using untreated cells
Standard deviations were calculated from triplicate samples.
followed by centrifugation and resuspension in drug-free
medium for 3 days. Table VI shows drug cytotoxicities for 3
day and 1 h exposures and also summarises DNA damaging
effects from preceding sections (to facilitate comparisons).
Generally, R factors after 1 h drug exposure were less than
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Figure 8 Quenching of Hoechst-33342 fluorescence by amsa-
crine. Suspensions of cells (106 cells/ml) from JL control 1 (A),
control 2 (0), AMSA (0) and adria (A) sublines and a solution
of calf thymus DNA (10 gmlP') (A) were incubated with
Hoechst-33342 for I h then incubated with various concentrations
of amsacrine for 1 h. Hoechst fluorescence for each sample was
then measured. Each point represent the mean of duplicate sam-
ples. (Standard deviations did not exceed ± 8%).
those from 3 day continuous exposure cytotoxicity experi-
ments. Most notably, resistance of the JL AMSA subline to
adriamycin cytotoxicity was negligible in the 1 h exposure
assay. Also, the 1 h cytotoxicity assay did not reflect the
relatively greater resistance of the JL adria subline to amsa-
crine-induced cytogenetic damage compared with the JL
AMSA subline.
Since production of H202 during adriamycin metabolism
may cause DNA breakage (Goormaghtigh & Ruysschaert,
1984), cytotoxicity of H202 to resistant and control sublines
was assayed in the 3 day cell growth assay. Average R
factors were 1.4 for the JL AMSA subline and 1.3 for the JL
adria subline. The fluorescence assay was used to measure
DNA breakage caused by incubation of JL sublines with
various concentrations of H202 for 1 h at 37°C. Concentra-
tions of H202 required to reduce the F values to 80% of the
values for untreated cells were 601AM, 11O1M and 120 1AM for
JL control, JL AMSA and JL adria sublines, respectively.
Assays for H202 induced cytogenetic damage were unsuccess-
ful, in that H202 reduced metaphases without causing aberra-
tions in all three cell lines.
Discussion
Although development of resistance to adriamycin or amsa-
crine was accompanied by cross resistance to several other
drugs, the resistant Jurkat sublines characterised in detail
here did not display the MDR phenotype previously des-
cribed by others (Beck, 1987; Moscow & Cowan, 1988;
Bradley et al., 1988). Thus, comparing resistant Jurkat sub-
lines to control drug sensitive sublines showed that drug
transport was unaltered, Pgp was not overexpressed, neither
a calcium channel blocker nor calmodulin inhibitor reversed
resistance and there was no evidence (in the form of HSRs or
ABRs) for gene amplification at the Pgp gene locus on the q
arm of chromosome 7. Despite these findings, it was noted
that drug resistance levels were similar to those of cell lines
previously shown to be MDR (Dalton et al., 1986). One line
we have not yet studied in any detail, JB1 adria, may exhibit
MDR with Pgp overexpression since it is cross resistant to
vincristine.
Although there was no significant difference between JL
resistant and control sublines in amsacrine (or adriamycin)
accumulation or retention, Figure 1 does show interesting
kinetics of amsacrine accumulation. At lower concentrations
of drug (Figure 1), intracellular amsacrine peaked then de-
creased whereas at higher drug concentrations intracellular
amsacrine did not reach plateau levels during the incubation
time and intracellular binding sites were not saturated.
For each of the four JL sublines incubated with 1 g1M to
101AM amsacrine for 1 h, intracellular to extracellular drug
concentration ratios increased from an average of 162 ± 8 to
343 ± 13. Therefore, Jurkat cells exhibited cooperative se-
questration of amsacrine as previously described for L1210
cells incubated with this drug (Zwelling et al., 1982), and our
results are in broad agreement with their postulated model of
drug movement. The site of drug sequestration cannot be
determined from these experiments but the Hoechst quench-
ing reversal results reinforce Zwelling's suggestion that drug
is sequestered apart from DNA. JL control or resistant sub-
lines did not show co-operative sequestration of adriamycin
since intracellular to extra-cellular drug concentration ratios
steadily decreased with increasing extracellular adriamycin
concentrations (between 5 and 20 ,LM).
Comparisons of proteins revealed two protein differences
between sublines which consistently correlated with the pres-
ence of drug resistance. Firstly, there were changes among
small polypeptides (<20K MW) extracted by SDS. Van der
Bliek et al. (1986) has detected elevated expression of the
19-20K MW calcium-binding cytosolic protein sorcin in re-
sistant cells. However, since differences between Jurkat sub-
lines were not detected in non-ionic detergent extracts, it is
unlikely that differences in our cells involved sorcin.
The second resistance-associated difference was an in-
creased amount of an 85K MW protein from JL AMSA, JBI
AMSA, JB2 AMSA, JL adria 200 and JBI adria compared
with drug-sensitive sublines, seen only after NP40 extraction
of radioiodinated surface proteins (Figure 2). Recently, Ha-
mada et al. (1988) described overexpression of an 85K MW
membrane protein in two adriamycin resistant human
tumour cell lines. Antibodies to this protein specifically
inhibited growth of resistant cells but did not affect drug
accumulation, so the functional role of the 85K MW protein
was not clear. It would be interesting to determine if our
85K MW protein is related to that observed by Hamada et
al.
From a large range of protein comparisons between resis-
tant and control Jurkat sublines (most data not shown here),
numerous protein differences occurred which were not con-
sistently associated with drug resistance, but were expressions
of phenotypic drift. Hence, it was essential to compare more
than one set of control and resistant sublines in deciding
which changes were drug resistance-related. A similar com-
ment applies to possible cytogenetic correlates of drug resis-
tance. For instance JL AMSA possessed rep(5;13), rep(7;13)
and 2der(3) chromosomes. Comparing this line alone with JL
control would have made these translocations appear
significant in resistance. However, the other drug resistant
lines studies including a subline of JL AMSA named JL AM,
showed other aberrations.
Numerous assays for enzyme activities suggested that ele-
vated GSH-related detoxification or altered cytochrome P450
functions did not contribute towards drug resistance of Jur-
kat sublines. In contrast, MDR MCF 7 human breast cancer
cells (selected for doxorubicin resistance) contained elevated
GSH transferase, GSH peroxidase, UDP glucuronyltrans-
ferase and sulpho-transferase activities, and reduced cyto-
chrome P450 inducibility compared with wild type cells
(Cowan et al., 1986; Sinha et al., 1987). Resistant JL cell
homogenates contained less of an NADPH-dependent activ-
ity which produced a more slowly migrating species (prob-
ably daunorubicinol) from 3H-DNR (Figure 3). The pH
optimum (close to pH 8.5) and NADPH dependence of the
activity are consistent with the presence of DNR reductase
activity (Ahmed, 1985). Ahmed suggested that intracellular
conversion of daunorubicin to daunorubicinol may favour
cell killing since lower lipophilicity of the cytotoxic 13-
dihydro derivatives would favour intracellular drug retention.
Indeed, in a study of daunorubicin resistant human myelo-
cytic cells (Vasanthakumar & Ahmed, 1986), it was suggested
that decreased DNR reductase activity could contribute to-
wards drug resistance. Thus, selection for adriamycin resis-
tant JL cells may have selected for cells containing less
aldo-keto reductase activity. However, it is unclear how selec-26 K. SNOW & W. JUDD
Table VI Collated data
Drug Amsacrine Adriamycin
JL AMSA JL adria JL AMSA JL adria
Assay (units) JL control (Rfactor) (Rfactor) JL control (Rfactor) (Rfactor)
3 day cytotoxicity IC50 0.078 3.6 (47) 2.0 (28) 0.3 0.146 (5) 0.329 (11)
(AM)
1 h cytotoxicity IC50 1.6 40 (25) 30 (18) 1.8 1.6 (0.9) 6 (4.5)
(tUM)
I h cytogenetic damage: < 1 20 (>20) 50 (>50) < 1.5 5 (>3.3) 25 (> 17)
50% undamaged
chromosomes CuM)
I h DNA breakage 0.12 11 (92) 7.5 (63) 4.5 19 (4.2) 16 (3.5)
(FADU): 80% duplex
DNA (EM)
PDC formation 0.7 43 (61) 5 (7.1) -
-2.5 fold stim (IM)
-5 fold stim (AM) 1.3 >50 (>38) 20 (15.4)
-plateau stim level ( x) 18 2.8 (6.4) 7.5 (2.4)
Summary ofcytotoxic and DNA damaging effects ofamsacrine and adriamycin with JL sublines. Cytotoxicity and DNA damaging
effects ofdrugs were assayed and compared using thecriteria shown in the farleftcolumn. Rfactors ofresistant sublines werecalculated
bydividing thedrugconcentration required tocause acertainlevel ofcytotoxicity orDNAdamage toresistantcellsby theconcentration
required to cause an identical effect with control cells.
tion for amsacrine resistance would select cells with altered
anthracycline metabolism. Possibly, the NADPH dependent
difference between resistant and control cells is mediated by a
factor other than daunorubicin reductase.
A fluorescence assay for DNA damage, a cytogenetic aber-
ration assay and an assay for DNA-protein complexes all
showed clearly that drug resistant cells were resistant to
DNA damage induced by either amsacrine or adriamycin.
Inhibiting DNA repair with araC showed that repair occur-
red in control cells but not resistant cells. Likewise, the
fluorescence assay for DNA damage (Figure 5) indicated that
control cells repaired more amsacrine induced damage than
did resistant cells. A caveat in both sets of results is the
possibility that high concentrations of drugs needed to pro-
duce effects in drug resistant cells may inhibit the DNA
repair processes in those cells. An additional possibility is
that DNA repair played a role in cell death. However, we
have no evidence that enhanced repair played a role in drug
resistance.
Although novobiocin is not a very specific inhibitor of
topo II, its use prior to cytotoxic drug exposure did affect
cells differentially, in that it reduced chromosome damage in
control cells but not in drug resistant cells.
Amsacrine and adriamycin resistant sublines were slightly
(less than two-fold) resistant to H202 induced DNA breakage
compared with control cells. The mechanism of this effect is
unclear, since levels ofprotecting enzymes are not elevated in
resistant cells. Although adriamycin has long been recognised
as having a free radical component in its mode of action, no
significant resistance to this mode of action is apparent in
any of the cells studied here.
Quenching by cytotoxic drugs of DNA stained with fluo-
rescent dye Hoechst 33342 revealed no significant differences
between drug resistant, control cells, and DNA in solution.
These results confirm that drug resistance is not mediated by
altered drug accumulation, transport, or reduced accessibility
to DNA in resistant cells. Removing cells from amsacrine
resulted in rapid restoration of Hoechst fluorescence, but
only limited efflux of amsacrine from cells. Hence, most of
the amsacrine is sequestered at unknown sites in the cells,
presumably at quite a high concentration. In contrast, adria-
mycin remained bound to DNA after removing cells from
drug solutions. Presumably, this tighter binding underlies the
ability of adriamycin to keep on causing breaks (Figure Sb),
and the apparent absence of repair seen here as well as by
others (Zwelling et al., 1981; Robson et al., 1987).
Both drug resistant JL sublines were significantly resistant
to stimulation of protein associated DNA breaks by amsac-
rine compared with the control subline (Figure 6). The JL
AMSA subline was more resistant than the JL adria subline,
reflecting relative resistances of these sublines to cytotoxic
effects of amsacrine. Thus, although the relationship between
cytotoxicity and PDC formation is unclear, resistance of JL
AMSA and JL adria sublines to amsacrine could at least
partially be mediated by resistance to PDC formation. Since
amsacrine produces PDCs by interaction with topoisomerase
II (Zwelling, 1985), it seems likely that the drug-topoiso-
merase-DNA interaction is altered in drug resistant JL sub-
lines. While it is not surprising that drug resistant JL sublines
resisted stimulation of PDC formation by adriamycin (Figure
7a), it was unexpected that adriamycin treated resistant cells
apparently contained fewer PDCs than untreated cells. It was
also unusual that a 2 h incubation of resistant or control JL
cells with adriamycin apparently gave less stimulation of
PDC production than a 1 h incubation (Figure 7). One ex-
planation is that progressive fragmentation of DNA involv-
ing non-protein-associated breaks (perhaps involving free
radicals) occurred during the adriamycin treatment. Thus,
greater fragmentation of DNA would reduce the amount of
radiolabelled DNA in PDC complexes on filters, such that
PDC formation seemed lower.
Although in general the results were consistent with the
hypothesis that drug resistance is effected by alterations in
DNA-topoisomerase II-drug interactions, the data also sug-
gest differences in the mode of action, or resistance to amsa-
crine and adriamycin between JL AMSA and JL adria.
In all assays, JL adria cells were more resistant to amsa-
crine than to adriamycin although they were selected for
resistance to adriamycin. JL AMSA cells, were more resistant
to amsacrine than adriamycin in all assays (Table VI). Thus,
correlations with drugs rather than resistant cell type are
observed. This data strongly suggests that adriamycin acts in
part by a mechanism that is shared with amsacrine and
partly by a distinct mechanism, to which the adriamycin
resistant cells remain largely susceptible. Developing resis-
tance to adriamycin was more difficult than to amsacrine.
The peculiarities of PDC formation with adriamycin, and the
likelihood that the drug causes breaks in DNA apart from
those induced by topoisomerase II are consistent with this
possibility. Differences in amsacrine and adriamycin binding
to DNA as shown by the Hoechst fluorescence quenching
experiments have also been outlined.
In addition, Table VI contains several quite striking anom-
alies. For instance, in the fluorescence assay for DNA
damage, JL AMSA was more resistant to adriamycin than
JL adria, although JL adria was more resistant to adriamycin
than JL AMSA in all other assays. Comparing the relative
concentrations of amsacrine and adriamycin required to pro-
duce similar levels of cytotoxicity or DNA damage to the JL
control subline (Table VI): in cytotoxic or cytogenetic dam-
age assays, concentrations of amsacrine and adriamycin re-
quired to produce similar effects were less than 3-fold
different, but amsacrine was approximately 40-fold more
potent than adriamycin in producing DNA damage detectedDRUG RESISTANT CELL LINES 27
by the fluorescence assay. Resistance of JL adria to
cytogenetic damage by amsacrine was greater than that ofJL
AMSA, although JL AMSA was more resistant to amsacrine
in all other assays. This resistance was not associated with
commensurate resistance to PDC formation, so the effect did
not involve topoisomerase II. Since the cells had little resis-
tance to H202, resistance to free radical action was not
involved either. One possibility is that amsacrine and
adriamycin have other modes of action, not associated with
topoisomerase II or free radical action, to which the cells
have some resistance. For instance, amsacrine present at high
concentration in the sequestration site could affect other
cellular processes. The present results suggesting some
differences in the details of resistance between JL AMSA and
JL adria cells have been reinforced by our recent findings of
differences in their patterns of resistance to amsacrine
analogues (Finlay et al., 1990).
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